BioCentury

12:04 AM GMT, Aug 25, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Company News

FDA reviewers question Humira benefit in UC

FDA reviewers questioned whether Humira adalimumab from Abbott Laboratories (NYSE:ABT) provides a "clinically meaningful benefit" for ulcerative colitis (UC) patients given the drug's "serious" safety risks and the availability of Remicade infliximab

Read the full 329 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.